Here's a thread you can read from a satisfied customer:
www.healingwell.com/community/default.aspx?f=35&p=1&m=3533447#m3643084Here are a few points of caution, however:
• PC is rarely unifocal. After RP pathology, there is a only a single tumor in less than 1 in 5 men who were diagnosed with a single tumor. There are almost always small sites of cancer missed by MRIs or biopsies that are found later.
• All forms of thermal ablation suffer from the heat sink effect. That means heat flows away from the ablation site into surrounding tissue. Because of this there may be incomplete tumor destruction in the ablation zone and there can be thermal injury to other organs, depending on the site.
• Because of the two points above, there is a 20-30% "re-do" rate for focal ablation. I suspect increased risk to surrounding tissues with more re-dos.
• There is a theory, called the Index Tumor Theory, that speculates that all tumors spring from a mother tumor called the Index Tumor. This theory is highly suspect. There is evidence on both sides of the question. My guess is that it occurs in some but not all cases.
• Multiparametric MRIs, even when read by expert radiologists, are far from perfect. They are actually pretty bad at detecting Gleason 6, and can sometimes miss high grade cancer. It is unclear how well it works in ablated tissue. While Wolfster feels safe just monitoring that way, I think careful practitioners would not depend only on that, but would have you undergo periodic follow-up biopsies, possibly saturation biopsies.
• There is no validated was to monitor success using PSA. What is a "good" nadir? What kind of rise is indicative of biochemical recurrence?
• Given that there is lifetime monitoring of PSA and probably should have follow-up biopsies, what is the advantage of focal ablation over active surveillance for the low risk patient? Mark Emberton, one of the foremost practitioners (in the UK), recommends focal ablation only for intermediate risk patients for this reason.
• Unless you have really high end insurance, they will not cover the treatment or the re-dos. They may balk at serial mpMRIs as well.
I'm not against it, and I'm actually glad that it is being tried, although I hope it is tried very cautiously and with very careful monitoring. I raise these points so that you have your eyes
open and so that you don't only hear the voice of its advocates. It's also because of patients like you who are willing to be the guinea pigs that we make any advances.